Preparing For An Imminent Transformation In How We Treat Diseases

As medicines evolve towards biologics, gene and cell therapies, experts view nucleic acid amplification techniques (NAT) as suitable methods to ensure product safety in the face of new modalities, complex matrices, and tight production timelines. Mycoplasma testing is no exception.

At the PharmaLab Pre-Conference Workshop on Mycoplasma qPCR Testing in 2019, experts discussed what some practical considerations are for implementing NAT-based methods, where concrete recommendations are necessary, and how guidelines can remain relevant for new medicinal products.